-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Huntington's Disease Therapeutics Conference 2017 – Day 2
4 min read
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 2
-
Huntington's Disease Therapeutics Conference 2017 – Day 1
6 min read
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-
Enemy at the gates – huntingtin disrupts nuclear transport
7 min read
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-
FDA approves a new drug for symptoms of Huntington's disease
4 min read
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
-
Sheep leading the flock: metabolism and biomarkers in HD
8 min read
Sheep can help us to identify HD biomarkers and recognize metabolic changes that occur before symptoms develop.
-
Weeding out the truth: can cannabis improve Huntington’s?
8 min read
What can individual experiences with cannabis tell us about Huntington's disease?
-
Huntingtin grabs a hammer: DNA repair in HD
8 min read
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
-
The benefits of migration, highlighted in Huntington's disease
6 min read
Is HD a developmental disease? HD stops neurons migrating in developing brain, but maybe we can get them going again
-
Treasure your exceptions – using outliers to understand Huntington's disease onset and progression
7 min read
A new study provides the framework for finding factors that affect the onset and progression of HD
-
A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
7 min read
What if some problems in HD were due to something other than a harmful protein?
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
